Drug Profile


Alternative Names: anti-HPV-16 E6 TCR; HPV-16 E6 TCR gene therapy

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 T cell receptor expression modulators; Immunologic cytotoxicity; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anal cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer; Vulvovaginal cancer

Most Recent Events

  • 03 Oct 2017 Gilead Sciences acquired Kite Pharma
  • 29 Jun 2017 National Cancer Institute plans a phase I trial for Cervical intraepithelial neoplasia in USA (NCT03197025)
  • 02 Jun 2017 Adverse events and efficacy data from a phase II trial in HPV-associated Anal cancer, Cervical cancer, Oropharyngeal cancer, Penile cancer, Vulvovaginal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top